ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Metformin

Also written as “metformin”, “Metformin XR” and “Fenofibrate /Metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Obesity · Fasting · Polycystic Ovary Syndrome, led by 48 companies.

Drug pageMetformin: every studyMany companies study it; this page follows only the 215 they lead. All 1,290 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 9, 2005215 company-led studies, 7 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only290 open or runningphase 3since Nov 9, 2005Nov 9, 2005none ahead
Merckits history only190 open or runningphase 4since Oct 9, 2009Feb 15, 2005none ahead
Sanofi160 open or runningphase 4since Jul 28, 2006Sep 30, 2002none ahead
GlaxoSmithKlineits history only140 open or runningphase 4since Oct 17, 2005Sep 3, 2003none ahead
Takedaits history only120 open or runningphase 4since Sep 17, 2008Jul 30, 2008none ahead
Merck KGaA, Darmstadt, Germanyits history only90 open or runningphase 4since Dec 30, 2011Dec 30, 2011none ahead
Teva Pharmaceutical Industriesits history only90 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
Viatrisits history only80 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
ADIUMits history only70 open or runningno phasesince Jun 3, 2026Jun 3, 2026none ahead
LG Chemits history only70 open or runningphase 3since Feb 6, 2013Aug 22, 2011none ahead

Also a collaborator on its studies: Parexel, PT Pharma Metric Labs, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly and Merck, S.L., Spain.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Sep 30, 2002.

  1. Jul 28, 2006Phase 4 study in Diabetes Mellitus, Type 2NCT00358124 · 220 enrolled · United States
  2. Jun 27, 2008Phase 4 study in Diabetes Mellitus, Type 2NCT00708578 · 99 enrolled · South Korea
  3. Sep 17, 2008Phase 3 study in Diabetes Mellitus, Type 2NCT00754689 · United States
  4. Oct 31, 2008Phase 3 study in Diabetes Mellitus, Type 2NCT00783744 · 375 enrolled · Austria, Finland, France and more
  5. Feb 25, 2009Phase 3 study in Diabetes Mellitus, Type 2NCT00851903 · 112 enrolled · United States, Austria, Brazil and more
  6. Jun 18, 2009Phase 3 study in Diabetes Mellitus, Type 2NCT00924573 · 189 enrolled · Japan
  7. Jun 14, 2010Phase 4 study in Diabetes Mellitus, Type 2NCT01144728 · 172 enrolled · Kazakhstan
  8. Sep 16, 2010Phase 4 study in Diabetes Mellitus, Type 2NCT01204580 · 40 enrolled · Indonesia
  9. Oct 24, 2011Phase 3 study in Diabetes Mellitus, Type 2NCT01459809 · 538 enrolled · Algeria, Colombia, Egypt and more
  10. Jan 16, 2012Phase 3 study in Diabetes Mellitus, Type 2NCT01517412 · 451 enrolled · United States, Canada, Czech Republic and more
  11. Mar 5, 2012Phase 1 study in HealthyNCT01551615 · 14 enrolled · United States
  12. Jan 3, 2014Phase 4 study in Diabetes Mellitus, Type 2NCT02027753 · 109 enrolled · Korea, Republic of
  13. Oct 17, 2014Phase 2 study in Diabetes Mellitus, Type 2NCT02274740 · 2 enrolled
  14. Mar 24, 2015Phase 1 study in Diabetes Mellitus, Type 2NCT02411825 · 76 enrolled · Germany

TargetBeta

“Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor”ChEMBL 37, by rule

Studies

All 16 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02411825Diabetes Mellitus, Type 2 · Germany1CompletedJan 201676
NCT02274740Diabetes Mellitus, Type 22TerminatedAug 20152
NCT02027753Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedApr 2015109
NCT01551615Healthy · United States1CompletedJun 201214
NCT01517412Diabetes Mellitus, Type 2 · United States, Canada, Czech Republic and more3CompletedMay 2013451
NCT01459809Diabetes Mellitus, Type 2 · Algeria, Colombia, Egypt and more3CompletedJan 2014538
NCT01204580Diabetes Mellitus, Type 2 · Indonesia4CompletedMar 201240
NCT01144728Diabetes Mellitus, Type 2 · Kazakhstan4CompletedDec 2010172
NCT00924573Diabetes Mellitus, Type 2 · Japan3CompletedMar 2010189
NCT00851903Diabetes Mellitus, Type 2 · United States, Austria, Brazil and more3CompletedSep 2011112
NCT00783744Diabetes Mellitus, Type 2 · Austria, Finland, France and more3CompletedAug 2003375
NCT00754689Diabetes Mellitus, Type 2 · United States3WithdrawnNov 20080
NCT00708578Diabetes Mellitus, Type 2 · South Korea4CompletedDec 200999
NCT00358124Diabetes Mellitus, Type 2 · United States4Completed220
NCT00353691Diabetes Mellitus, Type 2 · United States3Completed100
NCT00046462Diabetes Mellitus · United States3CompletedNov 2004240

How it is read

Names in the registry

  • “Metformin”, 95 entries
  • “metformin”, 33 entries
  • “Metformin XR”, 11 entries
  • “Fenofibrate /Metformin”, 6 entries
  • “Sitagliptin/Metformin FDC”, 5 entries

Codes read as this program: EFB0027.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.